Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis-Reference-Cited by-同舟云学术

Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis

Published:2020-09-29 Issue:6 Volume:32 Page:609-616
ISSN:1040-8711
Container-title:Current Opinion in Rheumatology
language:en
Short-container-title:

Author:

Narain Sonali,Berman Nicola,Furie Richard

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Rheumatology

Reference61 articles.

1. A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis [abstract];Furie;Arthritis Rheumatol,2019

2. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial;Navarra;Lancet,2011

3. Sjogren's syndrome: old and new therapeutic targets;Mavragani;J Autoimmun,2020

4. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome;Bowman;Arthritis Rheumatol,2017

5. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study;Mariette;Ann Rheum Dis,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovations in Cutaneous Lupus;Dermatologic Clinics;2024-09

2. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial;Lupus Science & Medicine;2023-08

3. Advances in natural products and antibody drugs for SLE: new therapeutic ideas;Frontiers in Pharmacology;2023-07-10

4. Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?;Current Issues in Molecular Biology;2023-05-15

5. Care about the flare: the importance of avoiding lupus nephritis recurrence;Nephrology Dialysis Transplantation;2022-12-07